The Quantellect read.As of Nov 19, 2026, 6 active firms cover Upstream Bio, Inc: 4 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $9.00 to $50.00 (about 5.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $29.67 sits 1326% above the current $2.08. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.83 next quarter toward $-2.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy467%
Neutral233%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$29.67
+1326.3% upside
Average target across 6 active firms as of Nov 19, 2026 vs $2.08 current
Highest Target$50.00
Average Target$29.67
Lowest Target$9.00
Detailed analyst forecasts for UPB
Showing 1–5 of 5 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 4 of 6 active firms rate UPB a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
UPB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.83
Range $-1.03 – $-0.61 · 3 analysts · +10% YoY
Next period, 3 analysts expect Upstream Bio, Inc. to earn $-0.83 a share (range $-1.03 – $-0.61), versus $-0.75 a year earlier. Full-year consensus is $-2.97, growing to $-2.63 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $2.5M, rising to $975.3K next year.
Top analysts covering Upstream Bio, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on UPB.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$36.00+1630.8% to target
Overall win rate
49%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$75.00+3505.8% to target
Overall win rate
30%
+ Follow
#3
TR
Tessa Romero
JP Morgan
Neutral
$9.00+332.7% to target
Coverage
—
+ Follow
#4
DB
Danielle Brill
Truist Securities
Buy
$25.00+1101.9% to target
Coverage
—
+ Follow
#5
Joseph Catanzaro
Mizuho
Buy
$50.00+2303.8% to target
Coverage
—
+ Follow
UPB stock forecast FAQ
What is UPB's average 12-month price target?+
The 6 active firms with a live target average $29.67 for Upstream Bio, Inc. over the next 12 months, ranging from a $50.00 high to a $9.00 low, as of Nov 19, 2026.
Is UPB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for UPB?+
The Street-high target is $50.00 (Mizuho), and the Street-low is $9.00 (JP Morgan). The average of all 6 active-firm targets is $29.67.
How many active Wall Street firms cover UPB?+
6 active firms have a recognized rating on Upstream Bio, Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering UPB?+
Among analysts who currently cover UPB, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #155). Their current call is Buy with a $36.00 target.
What is Upstream Bio, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.83 per share (range $-1.03 – $-0.61) across 3 analysts. Full-year EPS is projected at $-2.97, rising to $-2.63 the following year.
How much revenue is Upstream Bio, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $2.5M, growing to $975.3K next year.
Have analysts been upgrading or downgrading UPB lately?+
As of Nov 19, 2026, 4 of 6 active firms rate UPB a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their UPB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.